Parallel Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Parallel Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-43	Closed	-$7K	–	3637
2022 Q3	$7K	Buy	43 +13	+43%	+$1.93K	﹤0.01%	2180
2022 Q2	$4K	Sell	30 -1	-3%	-$128	﹤0.01%	2407
2022 Q1	$4K	Buy	31 +6	+24%	+$748	﹤0.01%	2431
2021 Q4	$3K	Sell	25 -109	-81%	-$13.9K	﹤0.01%	2643
2021 Q3	$19K	Buy	134 +116	+644%	+$14.5K	﹤0.01%	1780
2021 Q2	$2K	Hold	18	–	–	﹤0.01%	2669
2021 Q1	$1K	Hold	18	–	–	﹤0.01%	2769
2020 Q4	$2K	Hold	18	–	–	﹤0.01%	2385
2020 Q3	$1K	Hold	18	–	–	﹤0.01%	2541
2020 Q2	$1K	Buy	+18	New	+$958	﹤0.01%	2417

Other funds holding BHVN

Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Parallel Advisors's BHVN Position: Q4 2022 in Review

Parallel Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 43 shares — an estimated $7K sold.

Parallel Advisors first reported a position in BHVN in Q2 2020 and held it in 10 quarters. The position peaked at $19K in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

Parallel Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
Parallel Advisors sold 43 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $7K.
Parallel Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 10 quarters.
Parallel Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $19K in Q3 2021.
7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.